Chapter 4: Diagnosis of tuberculosis infection

References

• Schluger NW. The Pathogenesis of tuberculosis: the first one hundred (and twenty-three) years. Am J Respir Cell Mol Biol. 2005;32(4):251–256. doi:10.1165/rcmb.F293.
   PubMed Web of Science ®Google Scholar
• Campbell JR, Winters N, Menzies D. Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis. BMJ. 2020;368:m549. doi:10.1136/bmj.m549.
   PubMedGoogle Scholar
• International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bulletin of the World Health Organization. 1982;60(4):555–564.
   PubMedGoogle Scholar
• Campbell JR, Dowdy D, Schwartzman K. Treatment of latent infection to achieve tuberculosis elimination in low-incidence countries. PLoS Med. 2019;16(6):e1002824. doi:10.1371/journal.pmed.1002824.
   Web of Science ®Google Scholar
• Marais BJ, Chakaya J, Swaminathan S, et al. Tackling long-term morbidity and mortality after successful tuberculosis treatment. Lancet Infect Dis. 2020;20(6):641–642. doi:10.1016/S1473-3099(20)30167-5.
   PubMed Web of Science ®Google Scholar
• Huebner RE, Schein MF, John B, Bass J. The Tuberculin Skin Test. Clin Infect Dis. 1993;17(6):968–975. doi:10.1093/clinids/17.6.968.
   PubMed Web of Science ®Google Scholar
• Reichman LB. Hershfield ES. Reichman and Hershfield’s Tuberculosis: A Comprehensive, International Approach. 1400. New York: Informa Healthcare USA; 2006.
   Google Scholar
• Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet (London, England). 2000;356(9235):1099–1104. doi:10.1016/S0140-6736(00)02742-2.
   PubMed Web of Science ®Google Scholar
• Pai M, Riley LW, Colford JM. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis. 2004;4(12):761–776. doi:10.1016/S1473-3099(04)01206-X.
   PubMed Web of Science ®Google Scholar
• Abubakar I, Drobniewski F, Southern J, et al. Prognostic value of interferon-gamma release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study. Lancet Infect Dis. 2018;18(10):1077–1087. doi:10.1016/S1473-3099(18)30355-4.
   PubMed Web of Science ®Google Scholar
• Metcalfe JZ, Everett CK, Steingart KR, et al. Interferon-γ Release Assays for Active Pulmonary Tuberculosis Diagnosis in Adults in Low- and Middle-Income Countries: Systematic Review and Meta-analysis. The Journal of Infectious Diseases. 2011;204(suppl_4):S1120–S1129. doi:10.1093/infdis/jir410.
   Google Scholar
• Toossi Z, Ellner JJ. Mechanisms of Anergy in Tuberculosis. In: Shinnick TM, ed. Tuberculosis. Berlin Heidelberg: Springer-Verlag; 1996. p. 221–238. Current Topics in Microbiology and Immunology.
   Google Scholar
• Chiappini E, Fossi F, Bonsignori F, Sollai S, Galli L, de Martino M. Utility of Interferon-γ Release Assay Results to Monitor Anti-Tubercular Treatment in Adults and Children. Clin Ther. 2012;34(5):1041–1048. doi:10.1016/j.clinthera.2012.03.006.
   PubMed Web of Science ®Google Scholar
• Clifford V, He Y, Zufferey C, Connell T, Curtis N. Interferon gamma release assays for monitoring the response to treatment for tuberculosis: A systematic review. Tuberculosis (Edinb)). 2015;95(6):639–650. doi:10.1016/j.tube.2015.07.002.
   PubMed Web of Science ®Google Scholar
• Mancuso JD, Mody RM, Olsen CH, Harrison LH, Santosham M, Aronson NE. The Long-term Effect of Bacille Calmette-Guérin Vaccination on Tuberculin Skin Testing: A 55-Year Follow-Up Study. Chest. 2017;152(2):282–294. doi:10.1016/j.chest.2017.01.001.
   Web of Science ®Google Scholar
• Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16(11):1269–1278. doi:10.1016/S1473-3099(16)30216-X.
   PubMed Web of Science ®Google Scholar
• Moayedi-Nia S, Barss L, Oxlade O, et al. The mTST – An mHealth approach for training and quality assurance of tuberculin skin test administration and reading. Plos One. 2019;14(4):e0215240. doi:10.1371/journal.pone.0215240.
   PubMed Web of Science ®Google Scholar
• McGill TB Centre. TST Training Videos. 2021. https://www.mcgill.ca/tb/resources#aTools. Accessed December 16, 2021.
   Google Scholar
• Menzies D, Pai M, Comstock G. Meta-analysis: New Tests for the Diagnosis of Latent Tuberculosis Infection: Areas of Uncertainty and Recommendations for Research. Ann Intern Med. 2007;146(5):340–354. doi:10.7326/0003-​4819-146-5-200703060-00006.
   PubMed Web of Science ®Google Scholar
• Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis. 2006;10(11):1192–1204.
   PubMed Web of Science ®Google Scholar
• Cobelens FG, Egwaga SM, van Ginkel T, Muwinge H, Matee MI, Borgdorff MW. Tuberculin skin testing in patients with HIV infection: limited benefit of reduced cutoff values. Clin Infect Dis. 2006;43(5):634–639. doi:10.1086/506432.
   PubMed Web of Science ®Google Scholar
• Pai M, Denkinger CM, Kik SV, et al. Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection. Clin Microbiol Rev. 2014;27(1):3–20. doi:10.1128/CMR.00034-13.
   PubMed Web of Science ®Google Scholar
• van Ingen J, de Zwaan R, Dekhuijzen R, Boeree M, van Soolingen D. Region of Difference 1 in Nontuberculous Mycobacterium Species Adds a Phylogenetic and Taxonomical Character. J Bacteriol. 2009;191(18):5865–5867. doi:10.1128/JB.00683-09.
   PubMed Web of Science ®Google Scholar
• Hong JY, Park SY, Kim A, Cho S-N, Hur Y-G. Comparison of QFT-Plus and QFT-GIT tests for diagnosis of M. tuberculosis infection in immunocompetent Korean subjects. J Thorac Dis. 2019;11(12):5210–5217. doi:10.21037/jtd.2019.12.11.
   PubMed Web of Science ®Google Scholar
• Shafeque A, Bigio J, Hogan CA, Pai M, Banaei N. Fourth-Generation QuantiFERON-TB Gold Plus: What Is the Evidence? J Clin Microbiol. 2020;58(9):e01950–19. doi:10.1128/JCM.01950-19.
   PubMed Web of Science ®Google Scholar
• Moon H-W, Gaur RL, Tien SS-H, Spangler M, Pai M, Banaei N. Evaluation of QuantiFERON-TB Gold-Plus in Health Care Workers in a Low-Incidence Setting. J Clin Microbiol. 2017;55(6):1650–1657. doi:10.1128/JCM.02498-16.
   PubMed Web of Science ®Google Scholar
• Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149(3):177–184. doi:10.7326/0003-4819-149-3-200808050-00241.
   PubMed Web of Science ®Google Scholar
• Oxford Immunotec. T-SPOT.TB Package Insert. 2017. http://www.oxfordimmunotec.com/international/wp-content/uploads/sites/3/Final-File-PI-TB-US-V6.pdf. Accessed December 16, 2021.
   Google Scholar
• QIAGEN. QFT-Plus Package Insert. 2019. https://www.quantiferon.com/us/wp-content/uploads/sites/13/2020/01/L1095849-R06-QFT-Plus-ELISA-IFU.pdf. Accessed December 16, 2021.
   Google Scholar
• Ho CS, Feng P-JI, Narita M, et al. Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study. The Lancet Infectious Diseases. 2021;0(0). 2022;22(1):85–96. doi:10.1016/S1473-3099(21)00145-6.
   Google Scholar
• Ringshausen FC, Nienhaus A, Schablon A, Schlösser S, Schultze-Werninghaus G, Rohde G. Predictors of persistently positive Mycobacterium-tuberculosis-specific interferon-gamma responses in the serial testing of health care workers. BMC Infect Dis. 2010;10(1):220. doi:10.1186/1471-2334-10-220.
   PubMedGoogle Scholar
• Nemes E, Rozot V, Geldenhuys H, et al. Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of Mycobacterium tuberculosis Infection. Am J Respir Crit Care Med. 2017;196(5):638–648. doi:10.1164/rccm.201704-0817OC.
   PubMed Web of Science ®Google Scholar
• Sester M, Sotgiu G, Lange C, et al. Interferon-γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2011;37(1):100–111. doi:10.1183/09031936.00114810.
   PubMed Web of Science ®Google Scholar
• Ai L, Feng P, Chen D, Chen S, Xu H. Clinical value of interferon-γ release assay in the diagnosis of active tuberculosis. Exp Ther Med. 2019;18(2):1253–1257. doi:10.3892/etm.2019.7696.
   PubMed Web of Science ®Google Scholar
• Laurenti P, Raponi M, de Waure C, Marino M, Ricciardi W, Damiani G. Performance of interferon-γ release assays in the diagnosis of confirmed active tuberculosis in immunocompetent children: a new systematic review and meta-analysis. BMC Infect Dis. 2016;16(1):131. doi:10.1186/s12879-016-1461-y.
   PubMedGoogle Scholar
• Sollai S, Galli L, de Martino M, Chiappini E. Systematic review and meta-analysis on the utility of Interferon-gamma release assays for the diagnosis of Mycobacterium tuberculosis finfection in children: a 2013 update. BMC Infect Dis. 2014;14(S1):S6. doi:10.1186/1471-2334-14-S1-S6.
   PubMedGoogle Scholar
• Santin M, Muñoz L, Rigau D. Interferon-γ Release Assays for the Diagnosis of Tuberculosis and Tuberculosis Infection in HIV-Infected Adults: A Systematic Review and Meta-Analysis. PLOS One. 2012;7(3):e32482. doi:10.1371/journal.pone.0032482.
   PubMed Web of Science ®Google Scholar
• Unsal A, Ahbap E, Basturk T, et al. Tuberculosis in dialysis patients: a nine-year retrospective analysis. J Infect Dev Ctries. 2013;7(3):208–213. doi:10.3855/jidc.2664.
   PubMed Web of Science ®Google Scholar
• Chung WK, Zheng ZL, Sung JY, et al. Validity of interferon-γ-release assays for the diagnosis of latent tuberculosis in haemodialysis patients. Clin Microbiol Infect. 2010;16(7):960–965. doi:10.1111/j.1469-0691.2009.02949.x.
   PubMed Web of Science ®Google Scholar
• Ates G, Yildiz T, Danis R, et al. Incidence of tuberculosis disease and latent tuberculosis infection in patients with end stage renal disease in an endemic region. Ren Fail. 2010;32(1):91–95. doi:10.3109/08860220903367528.
   PubMed Web of Science ®Google Scholar
• Menzies R, Vissandjee B. Effect of bacille Calmette-Guérin vaccination on tuberculin reactivity. Am Rev Respir Dis. 1992;145(3):621–625. doi:10.1164/ajrccm/145.3.621.
   PubMedGoogle Scholar
• Karalliedde S, Katugaha LP, Uragoda CG. Tuberculin response of Sri Lankan children after BCG vaccination at birth. Tubercle. 1987;68(1):33–38. doi:10.1016/0041-3879(87)90005-5.
   PubMedGoogle Scholar
• Marcus JH, Khassis Y. The tuberculin sensitivity in BCG vaccinated infants and children in Israel. Acta Tuberc Pneumol Scand. 1965;46(2):113–122.
   PubMedGoogle Scholar
• Lifschitz M. The Value of the Tuberculin Skin Test as a Screening Test for Tuberculosis among BCG-Vaccinated Children. Pediatrics. 1965;36(4):624–627.
   PubMed Web of Science ®Google Scholar
• Dawar M, Clark M, Deeks SL, Walop W, Ahmadipour N. A fresh look at an old vaccine: Does BCG have a role in 21st Century Canada? International Journal of Circumpolar Health. 2004;63(sup2):230–236. doi:10.3402/ijch.v63i0.17908.
   PubMedGoogle Scholar
• Campbell JR, Chen W, Johnston J, et al. Latent tuberculosis infection screening in immigrants to low-incidence countries: a meta-analysis. Mol Diagn Ther. 2015;19(2):107–117. doi:10.1007/s40291-015-0135-6.
   PubMed Web of Science ®Google Scholar
• Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M. The BCG World Atlas: A Database of Global BCG Vaccination Policies and Practices. PLoS Med. 2011;8(3):e1001012 doi:10.1371/journal.pmed.1001012.
   PubMed Web of Science ®Google Scholar
• Oh CE, Ortiz-Brizuela E, Bastos ML, Menzies D. Comparing the Diagnostic Performance of QuantiFERON-TB Gold Plus to Other Tests of Latent Tuberculosis Infection: A Systematic Review and Meta-analysis. Clin Infect Dis. 2021;73(5):e1116–e1125. doi:10.1093/cid/ciaa1822.
   PubMed Web of Science ®Google Scholar
• Cattamanchi A, Smith R, Steingart KR, et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2011;56(3):230–238. doi:10.1097/QAI.0b013e31820b07ab.
   PubMed Web of Science ®Google Scholar
• Huo Z-y, Peng L. Accuracy of the interferon-γ release assay for the diagnosis of active tuberculosis among HIV-seropositive individuals: a systematic review and meta-analysis. BMC Infect Dis. 2016;16(1):350. doi:10.1186/s12879-016-1687-8.
   PubMedGoogle Scholar
• Petruccioli E, Chiacchio T, Navarra A, et al. Effect of HIV-infection on QuantiFERON-plus accuracy in patients with active tuberculosis and latent infection. J Infect. 2020;80(5):536–546. doi:10.1016/j.jinf.2020.02.009.
   PubMed Web of Science ®Google Scholar
• Ledesma JR, Ma J, Zheng P, Ross JM, Vos T, Kyu HH. Interferon-gamma release assay levels and risk of progression to active tuberculosis: a systematic review and dose-response meta-regression analysis. BMC Infect Dis. 2021;21(1):467. doi:10.1186/s12879-021-06141-4.
   PubMed Web of Science ®Google Scholar
• Gupta RK, Lipman M, Jackson C, et al. Quantitative IFN-γ Release Assay and Tuberculin Skin Test Results to Predict Incident Tuberculosis. A Prospective Cohort Study. Am J Respir Crit Care Med. 2020;201(8):984–991. doi:10.1164/rccm.201905-0969OC.
   PubMed Web of Science ®Google Scholar
• Dale KD, Karmakar M, Snow KJ, Menzies D, Trauer JM, Denholm JT. Quantifying the rates of late reactivation tuberculosis: a systematic review. Lancet Infect Dis. 2021;21(10):e303–e317. doi:10.1016/S1473-3099(20)30728-3.
   Web of Science ®Google Scholar
• Zhou G, Luo Q, Luo S, et al. Interferon-γ release assays or tuberculin skin test for detection and management of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2020;20(12):1457–1469. doi:10.1016/S1473-3099(20)30276-0.
   PubMed Web of Science ®Google Scholar
• Gupta RK, Calderwood CJ, Yavlinsky A, et al. Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings. Nat Med. 2020;26(12):1941–1949. doi:10.1038/s41591-020-1076-0.
   PubMed Web of Science ®Google Scholar
• Martinez L, Cords O, Horsburgh CR, et al. The Risk of Tuberculosis in Children After Close Exposure: An Individual-Participant Meta-analysis Including 137,647 Children from 46 Cohort Studies. Lancet (London, England). 2020;395(10228):973–984. doi:10.1016/S0140-6736(20)30166-5.
   PubMed Web of Science ®Google Scholar
• Ward H, Stewart S, Al-Azem A, Reeder B, Hoeppner V. Quantifying local TB risk factors and determining the relative cost of treatment of latent TB infection to prevent tuberculosis. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 2017;1(4):191–198. doi:10.1080/24745332.2017.1387879.
   Web of Science ®Google Scholar
• Cook VJ, Hernández-Garduño E, Elwood RK. Risk of tuberculosis in screened subjects without known risk factors for active disease. The International Journal of Tuberculosis and Lung Disease. 2008;12(8):903–908.
   PubMed Web of Science ®Google Scholar
• Horsburgh CR, O’Donnell M, Chamblee S, et al. Revisiting rates of reactivation tuberculosis: a population-based approach. Am J Respir Crit Care Med. 2010;182(3):420–425. doi:10.1164/rccm.200909-1355OC.
   Web of Science ®Google Scholar
• Lawn SD, Harries AD, Williams BG, et al. Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it? The international journal of tuberculosis and lung disease: the official journal of the International Union against. Int J Tuberc Lung Dis. 2011;15(5):571–581. doi:10.5588/ijtld.10.0483.
   Web of Science ®Google Scholar
• Ross JM, Badje A, Rangaka MX, et al. Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. Lancet Hiv. 2021;8(1):e8–e15. doi:10.1016/S2352-3018(20)30299-X.
   PubMed Web of Science ®Google Scholar
• Schluger NW, Perez D, Liu YM. Reconstitution of immune responses to tuberculosis in patients with HIV infection who receive antiretroviral therapy. Chest. 2002;122(2):597–602. doi:10.1378/chest.122.2.597.
   Web of Science ®Google Scholar
• Van Ginderdeuren E, Bassett J, Hanrahan CF, Mutunga L, Van Rie A. High conversion of tuberculin skin tests during the first year of antiretroviral treatment among South African adults in primary care. AIDS. 2021;35(11):1775–1784. doi:10.1097/QAD.0000000000002952.
   PubMed Web of Science ®Google Scholar
• Kirenga BJ, Worodria W, Massinga-Loembe M, et al. Tuberculin skin test conversion among HIV patients on antiretroviral therapy in Uganda. Int j Tuberc Lung Dis. 2013;17(3):336–341. doi:10.5588/ijtld.12.0298.
   PubMed Web of Science ®Google Scholar
• Talebi-Taher M, Abbasian L, Alavi-Niakou SN, Javad-Moosavi SA, Pahlavani S. Tuberculin Skin Test Conversion among Individuals with Human Immunodeficiency Virus Infection on Antiretroviral Therapy in a Referral Teaching Hospital, Tehran, Iran. Tanaffos. 2017;16(3):201–206.
   PubMedGoogle Scholar
• Girardi E, Palmieri F, Zaccarelli M, et al. High incidence of tuberculin skin test conversion among HIV-infected individuals who have a favourable immunological response to highly active antiretroviral therapy. AIDS. 2002;16(14):1976–1979. doi:10.1097/00002030-200209270-00021.
   PubMed Web of Science ®Google Scholar
• Doshi S, Chen TF, Zapata J, et al. Risk factors for tuberculin skin test conversion among HIV-infected patients in New York City. Int J Infect Dis. 2012;16(7):e518–e521. doi:10.1016/j.ijid.2012.03.002.
   PubMed Web of Science ®Google Scholar
• Cho PJ-Y, Wu C-Y, Johnston J, Wu M-Y, Shu C-C, Lin H-H. Progression of chronic kidney disease and the risk of tuberculosis: an observational cohort study. Int J Tuberc Lung Dis. 2019;23(5):555–562. doi:10.5588/ijtld.18.0225.
   PubMed Web of Science ®Google Scholar
• Kumar DS, Ronald LA, Romanowski K, et al. Risk of active tuberculosis in migrants diagnosed with cancer: a retrospective cohort study in British Columbia, Canada. BMJ Open. 2021;11(3):e037827 doi:10.1136/bmjopen-2020-037827.
   PubMed Web of Science ®Google Scholar
• Cheng MP, Abou Chakra CN, Yansouni CP, et al. Risk of Active Tuberculosis in Patients with Cancer: A Systematic Review and Meta-Analysis. Clin Infect Dis. 2017;64(5):635–644. doi:10.1093/cid/ciw838.
   PubMed Web of Science ®Google Scholar
• Leegaard A, Riis A, Kornum JB, et al. Diabetes, Glycemic Control, and Risk of Tuberculosis: A population-based case-control study. Diabetes Care. 2011;34(12):2530–2535. doi:10.2337/dc11-0902.
   PubMed Web of Science ®Google Scholar
• Piette JD, Kerr EA. The Impact of Comorbid Chronic Conditions on Diabetes Care. Diabetes Care. 2006;29(3):725–731. doi:10.2337/diacare.29.03.06.dc05-2078.
   PubMed Web of Science ®Google Scholar
• Restrepo BI, Fisher-Hoch SP, Pino PA, et al. Tuberculosis in Poorly Controlled Type 2 Diabetes: Altered Cytokine Expression in Peripheral White Blood Cells. Clin Infect Dis. 2008;47(5):634–641. doi:10.1086/590565.
   PubMed Web of Science ®Google Scholar
• Nolan CM, Elarth AM. Tuberculosis in a cohort of Southeast Asian Refugees. A five-year surveillance study. Am Rev Respir Dis. 1988;137(4):805–809. doi:10.1164/ajrccm/137.4.805.
   PubMedGoogle Scholar
• Grzybowski S, McKinnon NE, Tuters L, Pinkus G, Philipps R. Reactivations in Inactive Pulmonary Tuberculosis. American Review of Respiratory Disease. 1966;93(3P1):352–361. doi:10.1164/arrd.1966.93.3P1.352.
   Google Scholar
• Grzybowski S, Fishaut H, Rowe J, Brown A. Tuberculosis among patients with various radiologic abnormalities, followed by the chest clinic service. Am Rev Respir Dis. 1971;104(4):605–608. doi:10.1164/arrd.1971.104.4.605.
   PubMedGoogle Scholar
• Horwitz O, Wilbek E, Erickson PA. Epidemiological basis of tuberculosis eradication. 10. Longitudinal studies on the risk of tuberculosis in the general population of a low-prevalence area. Bull World Health Organ. 1969;41(1):95–113.
   PubMed Web of Science ®Google Scholar
• Lönnroth K, Williams BG, Stadlin S, Jaramillo E, Dye C. Alcohol use as a risk factor for tuberculosis - a systematic review. BMC Public Health. 2008;8(1):289 doi:10.1186/1471-2458-8-289.
   PubMedGoogle Scholar
• Maurya V, Vijayan VK, Shah A. Smoking and tuberculosis: an association overlooked. The International Journal of Tuberculosis and Lung Disease: The Official Journal of the International Union against Tuberculosis and Lung Disease. 2002;6(11):942–951.
   PubMed Web of Science ®Google Scholar
• Bates MN, Khalakdina A, Pai M, Chang L, Lessa F, Smith KR. Risk of tuberculosis from exposure to tobacco smoke: a systematic review and meta-analysis. Arch Intern Med. 2007;167(4):335–342. doi:10.1001/archinte.167.4.335.
   PubMedGoogle Scholar
• Lin H-H, Ezzati M, Murray M. Tobacco smoke, indoor air pollution and tuberculosis: a systematic review and meta-analysis. PLoS Med. 2007;4(1):e20. doi:10.1371/journal.pmed.0040020.
   PubMed Web of Science ®Google Scholar
• Jeon CY, Murray MB. Diabetes Mellitus Increases the Risk of Active Tuberculosis: A Systematic Review of 13 Observational Studies. PLoS Med. 2008;5(7):e152. doi:10.1371/journal.pmed.0050152.
   PubMed Web of Science ®Google Scholar
• Comstock GW, Edwards LB, Livesay VT. Tuberculosis morbidity in the U.S. Navy: its distribution and decline. Am Rev Respir Dis. 1974;110(5):572–580. doi:10.1164/arrd.1974.110.5.572.
   Google Scholar
• Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc. 1970;26:28–106.
   PubMedGoogle Scholar
• Brode SK, Jamieson FB, Ng R, et al. Increased risk of mycobacterial infections associated with anti-rheumatic medications. Thorax. 2015;70(7):677–682. doi:10.1136/thoraxjnl-2014-206470.
   PubMed Web of Science ®Google Scholar
• Muñoz L, Santin M, Alcaide F, OPTIMIST Study Team, et al. QuantiFERON-TB Gold In-Tube as a Confirmatory Test for Tuberculin Skin Test in Tuberculosis Contact Tracing: A Noninferiority Clinical Trial. Clin Infect Dis. 2018;66(3):396–403. doi:10.1093/cid/cix745.
   PubMed Web of Science ®Google Scholar
• Tagmouti S, Slater M, Benedetti A, et al. Reproducibility of Interferon Gamma (IFN-γ) Release Assays. A Systematic Review. Ann Am Thorac Soc. 2014;11(8):1267–1276. doi:10.1513/AnnalsATS.201405-188OC.
   PubMedGoogle Scholar
• Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med. 1999;159(1):15–21. doi:10.1164/ajrccm.159.1.9801120.
   PubMed Web of Science ®Google Scholar
• Whitworth WC, Hamilton LR, Goodwin DJ, et al. Within-Subject Interlaboratory Variability of QuantiFERON-TB Gold In-Tube Tests. PLOS One. 2012;7(9):e43790. doi:10.1371/journal.pone.0043790.
   PubMed Web of Science ®Google Scholar
• Banaei N, Gaur RL, Pai M. Interferon Gamma Release Assays for Latent Tuberculosis: What Are the Sources of Variability? J Clin Microbiol. 2016;54(4):845–850. doi:10.1128/JCM.02803-15.
   PubMedGoogle Scholar
• Metcalfe JZ, Cattamanchi A, McCulloch CE, Lew JD, Ha NP, Graviss EA. Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice. Am J Respir Crit Care Med. 2013;187(2):206–211. doi:10.1164/rccm.201203-0430OC.
   PubMed Web of Science ®Google Scholar
• Banaei N, Pai M. Detecting New Mycobacterium tuberculosis Infection. Time for a More Nuanced Interpretation of QuantiFERON Conversions. Am J Respir Crit Care Med. 2017;196(5):546–547. doi:10.1164/rccm.201707-1543ED.
   PubMed Web of Science ®Google Scholar
• Sepulveda RL, Ferrer X, Latrach C, Sorensen RU. The influence of Calmette-Guérin bacillus immunization on the booster effect of tuberculin testing in healthy young adults. Am Rev Respir Dis. 1990;142(1):24–28. doi:10.1164/ajrccm/142.1.24.
   PubMedGoogle Scholar
• Feld R, Bodey GP, Gröschel D. Mycobacteriosis in Patients With Malignant Disease. Arch Intern Med. 1976;136(1):67–70. doi:10.1001/archinte.1976.03630010051009
   PubMed Web of Science ®Google Scholar
• Dorman SE, Belknap R, Graviss EA, for the Tuberculosis Epidemiologic Studies Consortium, et al. Interferon-γ Release Assays and Tuberculin Skin Testing for Diagnosis of Latent Tuberculosis Infection in Healthcare Workers in the United States. Am J Respir Crit Care Med. 2013;189(1):131203133239003–131203133239087. doi:10.1164/rccm.201302-0365OC.
   Web of Science ®Google Scholar
• Sosa LE. Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from the National Tuberculosis Controllers Association and CDC, 2019. MMWR Morbidity and Mortality Weekly Report. 2019;68(19):439–443. doi:10.15585/mmwr.mm6819a3.
   PubMed Web of Science ®Google Scholar
• Campbell JR, Trajman A, Cook VJ, et al. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials. Lancet Infect Dis. 2020;20(3):318–329. doi:10.1016/S1473-3099(19)30575-4.
   PubMed Web of Science ®Google Scholar
• Verma G, Chuck AW, Jacobs P. Tuberculosis screening for long-term care: a cost-effectiveness analysis. Int J Tuberc Lung Dis. 2013;17(9):1170–1177. doi:10.5588/ijtld.12.0934.
   PubMed Web of Science ®Google Scholar
• Reddy D, Walker J, White LF, et al. Latent Tuberculosis Infection Testing Practices in Long-Term Care Facilities, Boston, Massachusetts. J Am Geriatr Soc. 2017;65(6):1145–1151. doi:10.1111/jgs.14696.
   PubMed Web of Science ®Google Scholar
• Cadieux G, Fung C, Fitzgerald-Husek A, et al. Tuberculosis Screening on Admission to Long-Term Care Homes in Ontario. 2019.
   Google Scholar
• Khalil NJ, Kryzanowski JA, Mercer NJ, Ellis E, Jamieson F. Tuberculosis Outbreak in a Long-term Care Facility. Can J Public Health. 2013;104(1):e28–e32. doi:10.1007/BF03405650.
   PubMed Web of Science ®Google Scholar
• Dorken E, Grzybowski S, Allen EA. Significance of the Tuberculin Test in the Elderly. Chest. 1987;92(2):237–240. doi:10.1378/chest.92.2.237.
   PubMed Web of Science ®Google Scholar
• de Visser V, Sotgiu G, Lange C, TBNET, et al. False-negative interferon-γ release assay results in active tuberculosis: a TBNET study. Eur Respir J. 2015;45(1):279–283. doi:10.1183/09031936.00120214.
   Web of Science ®Google Scholar
• Bae W, Park KU, Song EY, et al. Comparison of the Sensitivity of QuantiFERON-TB Gold In-Tube and T-SPOT.TB According to Patient Age. Plos One. 2016;11(6):e0156917. doi:10.1371/journal.pone.0156917.
   PubMed Web of Science ®Google Scholar
• Khan A, Rebhan A, Seminara D, Szerszen A. Enduring Challenge of Latent Tuberculosis in Older Nursing Home Residents: A Brief Review. J Clin Med Res. 2019;11(6):385–390. doi:10.14740/jocmr3763.
   Google Scholar
• Menzies D, Gardiner G, Farhat M, Greenaway C, Pai M. Thinking in three dimensions: a web-based algorithm to aid the interpretation of tuberculin skin test results. The International Journal of Tuberculosis and Lung Disease: The Official Journal of the International Union against Tuberculosis and Lung Disease. 2008;12(5):498–505.
   PubMed Web of Science ®Google Scholar
• Youssef E, Wooltorton E. Serious allergic reactions following tuberculin skin tests. CMAJ. 2005;173(1):34–34. doi:10.1503/cmaj.050710.
   PubMed Web of Science ®Google Scholar
• Schatz M, Patterson R, Kloner R, Falk J. The prevalence of tuberculosis and positive tuberculin skin tests in a steroid-treated asthmatic population. Ann Intern Med. 1976;84(3):261–265. doi:10.7326/0003-4819-84-3-261.
   PubMed Web of Science ®Google Scholar
• Bovornkitti S, Kangsadal P, Sathirapat P, Oonsombatti P. Reversion and reconversion rate of tuberculin skin reactions in correction with the use of prednisone. Dis Chest. 1960;38:51–55. doi:10.1378/chest.38.1.51.
   PubMedGoogle Scholar
• Brody JA, Overfield T, Hammes LM. Depression of the Tuberculin Reaction by Viral Vaccines. N Engl J Med. 1964;271:1294–1296. doi:10.1056/NEJM196412172712505.
   PubMed Web of Science ®Google Scholar
• Howard TP, Solomon DA. Reading the Tuberculin Skin Test: Who, When, and How? Arch Intern Med. 1988;148(11):2457–2459. doi:10.1001/archinte.1988.00380110093020
   Google Scholar
• Duboczy BO, Brown BT. Multiple Readings and Determination of Maximal Intensity of Tuberculin Reaction. Am Rev Respir Dis. 1961;84(1):60–68. doi:10.1164/arrd.1961.84.1.60.
   PubMedGoogle Scholar
• Tarlo SM, Day JH, Mann P, Day MP. Immediate hypersensitivity to tuberculin. In vivo and in vitro studies. Chest. 1977;71(1):33–37. doi:10.1378/chest.71.1.33.
   PubMed Web of Science ®Google Scholar
• Rose W, Kitai I, Kakkar F, Read SE, Behr MA, Bitnun A. Quantiferon Gold-in-tube assay for TB screening in HIV infected children: influence of quantitative values. BMC Infect Dis. 2014;14:516. doi:10.1186/1471-2334-14-516.
   PubMed Web of Science ®Google Scholar
• Menzies R, Vissandjee B, Rocher I, St Germain Y. The booster effect in two-step tuberculin testing among young adults in Montreal. Ann Intern Med. 1994;120(3):190–198. doi:10.7326/0003-4819-120-3-199402010-00003.
   PubMed Web of Science ®Google Scholar
• Stead WW, To T. The significance of the tuberculin skin test in elderly persons. Ann Intern Med. 1987;107(6):837–842. doi:10.7326/0003-4819-107-6-837.
   PubMed Web of Science ®Google Scholar
• Salles CG, Ruffino-Netto A, Lapa-e-Silva JR, et al. The presence of a booster phenomenon among contacts of active pulmonary tuberculosis cases: a retrospective cohort. BMC Public Health. 2007;7(1):38. doi:10.1186/1471-2458-7-38.
   PubMedGoogle Scholar
• Dogan E, Erkoc R, Sayarlioglu H, Uzun K. Tuberculin Skin Test Results and the Booster Phenomenon in Two-Step Tuberculin Skin Testing in Hemodialysis Patients. Ren Fail. 2005;27(4):425–428. doi:10.1081/JDI-65379.
   PubMed Web of Science ®Google Scholar
• WHO. In press. Use of novel tuberculin skin tests for the diagnosis of TB infection. Geneva, Switzerland: World Health Organization.
   Google Scholar
• WHO. Use of alternative interferon-gamma release assays for the diagnosis of TB infection: WHO policy statement. 2022; Geneva, Switzerland: World Health Organization. https://www.who.int/publications/i/item/9789240042346. Accessed February 1, 2022.
   Google Scholar